

1 α ,25-dihydroxyvitamin D₃ inhibits uncoupling protein 2 expression in human adipocytes¹

HANG SHI, ANTHONY W. NORMAN,* WILLIAM H. OKAMURA,* ANINDITA SEN,[†]
AND MICHAEL B. ZEMEL²

University of Tennessee, Knoxville, Tennessee, 37996, USA; *University of California, Riverside, California, USA; and [†]Zen-Bio, Research Triangle Park, North Carolina, USA

SPECIFIC AIMS

This study was conducted to determine the role of 1 α ,25-dihydroxyvitamin D₃ (1 α ,25-(OH)₂-D₃) in modulating human adipocyte uncoupling protein 2 (UCP2) expression via genomic action mediated by nuclear vitamin D receptor.

PRINCIPAL FINDINGS

1. 1 α ,25-(OH)₂-D₃ inhibits human adipocyte basal, isoproterenol, and fatty acid-stimulated UCP2 expression

Figure 1, top panel, shows that 48 h treatment of human adipocytes with 1 nM 1 α ,25-(OH)₂-D₃ caused a 40% decrease in UCP2 mRNA ($P < 0.003$) whereas direct stimulation of Ca²⁺ influx with 10 mM KCl, a cell membrane depolarization agent, exerted no effect. Similar results were observed on UCP2 protein levels measured by Western blot ($P < 0.002$, Fig. 1, bottom panel). 10 nM isoproterenol caused a ~twofold increase in adipocyte UCP2 mRNA ($P < 0.002$), which was completely blocked by 1 α ,25-(OH)₂-D₃ but by only 20% by KCl. Although KCl inhibited isoproterenol-stimulated increases in UCP2 protein ($P < 0.006$), 1 α ,25-(OH)₂-D₃ exerted a more potent effect, reducing UCP2 protein below basal levels. Free fatty acids (oleic acid, linoleic acid, and stearic acid mixture) caused a ~twofold increase in UCP2 mRNA that was completely prevented by 1 α ,25-(OH)₂-D₃, but not by KCl. These data indicate that 1 α ,25-(OH)₂-D₃ inhibition of UCP2 expression is largely independent of its effects on Ca²⁺ influx or fatty acid flux.

2. Membrane vitamin D receptor does not mediate the inhibitory effect of 1 α ,25-(OH)₂-D₃ on human adipocyte UCP2 expression

To study whether membrane vitamin D receptor (mVDR) mediates this inhibition of 1 α ,25-(OH)₂-D₃ on adipocyte UCP2 expression, 1 α ,25-dihydroxylumisterol₃ (1 α ,25-(OH)₂-lumisterol₃), a specific mVDR agonist, and 1 β ,25-dihydroxyvitamin D (1 β ,25-(OH)₂-D₃), a specific mVDR antagonist, were used to treat

human adipocytes. 1 α ,25-(OH)₂-lumisterol₃ failed to exert an inhibitory effect on UCP2 mRNA, whereas 1 β ,25-(OH)₂-D₃ was unable to reverse 1 α ,25-(OH)₂-D₃-induced inhibition on UCP2 mRNA. Similarly, the mVDR agonist and antagonist exerted no effect on isoproterenol- and fatty acid-stimulated UCP2 expression. These data indicate that mVDR does not mediate the inhibitory effect of 1 α ,25-(OH)₂-D₃ on adipocyte UCP2 expression.

3. Nuclear vitamin D receptor mediates the inhibitory effect of 1 α ,25-(OH)₂-D₃ on human adipocyte UCP2 expression

We next investigated the role of the nuclear vitamin D receptor (nVDR) in mediating the inhibitory effect of 1 α ,25-(OH)₂-D₃ on adipocyte UCP2 expression. Using RT-PCR, we detected a 465 bp nVDR fragment in human adipocytes and preadipocytes. This was confirmed by Western blot analysis; using a nVDR monoclonal antibody, we detected a ~50 kDa protein. We then performed a transient transfection of antisense ODN to knock out the nVDR. A time course study shows that treatment with nVDR antisense ODN inhibited nVDR protein from 48 h through 96 h, whereas the mutant antisense ODN was without effect (**Fig. 2**, top panel). We then treated the nVDR knockout adipocytes with 1 α ,25-(OH)₂-D₃. **Figure 2** (bar graph) shows that 1 α ,25-(OH)₂-D₃ inhibited UCP2 mRNA by 60% in either control adipocytes or adipocytes treated with mutant ODN. However, 1 α ,25-(OH)₂-D₃ was unable to exert the inhibitory effect in nVDR knockout adipocytes. Similar results were observed on UCP2 protein levels measured by Western blot (**Fig. 2**, bottom). These data indicate that this inhibitory effect of 1 α ,25-(OH)₂-D₃ on UCP2 expression is mediated by the nVDR.

¹ To read the full text of this article, go to <http://www.fasebj.org/cgi/doi/10.1096/fj.02-0255fje>; to cite this article, use *FASEB J.* (September 5, 2002) 10.1096/fj.02-0255fje

² Correspondence: University of Tennessee, 1215 West Cumberland Avenue, #229, Knoxville, TN 37996-1900, USA. E-mail: mzemel@utk.edu




Figure 1. The effect of $1\alpha,25\text{-(OH)}_2\text{-D}_3$ on basal UCP2 mRNA (top panel) and protein level (bottom) in human adipocytes. Human adipocytes were treated with $1\alpha,25\text{-(OH)}_2\text{-D}_3$ (1 nM) or KCl (10 mM). UCP2 mRNA and protein level were measured by Northern blot and Western blot analysis, respectively. Upper panel: blot is representative of 4 similar experiments. * $P < 0.003$ vs. control; lower panel: blot is representative of 3 similar experiments. * $P < 0.002$ vs. control; data are expressed as mean \pm SE.

CONCLUSIONS

It is now well recognized that $1\alpha,25\text{-(OH)}_2\text{-D}_3$ generates biological responses via both genomic and nongenomic pathways. $1\alpha,25\text{-(OH)}_2\text{-D}_3$ generates genomic actions via binding to a specific nuclear hormone receptor, nVDR. Moreover, $1\alpha,25\text{-(OH)}_2\text{-D}_3$ generates rapid, nongenomic signal transduction, including modulation of calcium channels, via a putative membrane mVDR in a wide variety of cells.

Our previous and present data extend these observations by demonstrating that $1\alpha,25\text{-(OH)}_2\text{-D}_3$ elicits genomic and nongenomic action in adipocytes. We previously reported that $1\alpha,25\text{-(OH)}_2\text{-D}_3$ stimulates adipocyte $[\text{Ca}^{2+}]_i$, promotes lipogenesis, and inhibits lipolysis via a rapid nongenomic action. Data presented

here further demonstrate that $1\alpha,25\text{-(OH)}_2\text{-D}_3$ exerts an inhibitory effect on adipocyte UCP2 expression via a genomic action. Therefore, $1\alpha,25\text{-(OH)}_2\text{-D}_3$ appears to play an important role in modulating adipocyte lipid metabolism and energy homeostasis.




Figure 2. Nuclear vitamin D receptor (nVDR) knockout by antisense oligodeoxynucleotide (ODN) prevented the inhibitory effect of $1\alpha,25\text{-(OH)}_2\text{-D}_3$ on adipocyte UCP2 expression. A time course of nVDR knockout by antisense ODN; an equal amount of protein loading was achieved by sample DNA measurement and confirmed by SDS-PAGE visualized with Coomassie blue stain (top panel). Adipocytes were transfected with nVDR antisense ODN or mutant ODN as indicated. Lower panels: nVDR knockout by antisense ODN prevented the inhibitory effect of $1\alpha,25\text{-(OH)}_2\text{-D}_3$ on adipocyte UCP2 mRNA (bar graph) and protein (bottom panel). nVDR knockout adipocytes or adipocytes transfected with mutant ODN were treated with or without $1\alpha,25\text{-(OH)}_2\text{-D}_3$. UCP2 mRNA and protein were measured by quantitative real-time RT-PCR and Western blot, respectively.




Figure 3. $1\alpha,25\text{-(OH)}_2\text{-D}_3$ plays an important role in modulating adipocyte lipid metabolism and energy homeostasis via genomic and nongenomic actions. $1\alpha,25\text{-(OH)}_2\text{-D}_3$ exerts an inhibitory effect on adipocyte UCP2 expression via a genomic action mediated by nVDR. On the other hand, $1\alpha,25\text{-(OH)}_2\text{-D}_3$ stimulates adipocyte $[\text{Ca}^{2+}]_i$ via a putative mVDR and, subsequently, stimulates lipogenesis and inhibits lipolysis via nongenomic action. Accordingly, dietary calcium suppression of $1\alpha,25\text{-(OH)}_2\text{-D}_3$ decreases adipocyte $[\text{Ca}^{2+}]_i$, inhibits lipogenesis, stimulates lipolysis, and increases UCP2 expression, thereby reducing adiposity.

UCP2, a homologue of UCP1, is ubiquitously expressed, with the highest level in white adipose tissue. UCP2 has been shown to stimulate mitochondrial proton leak and therefore to exhibit a potential role in thermogenesis, energy metabolism, and obesity. Functional characterization of UCP2 promoter region has demonstrated several potent *cis*-acting regulatory elements, including multiple PPAR γ and thyroid hormone responsive elements. However, little is known regarding negative regulatory factors of UCP2 expression. Here we report that $1\alpha,25\text{-(OH)}_2\text{-D}_3$ exerts an inhibitory effect on UCP2 expression. The mechanism of this nVDR-mediated inhibition of UCP2 is not known. However, human and mouse UCP2 promoters do contain several *cis*-acting negative regulatory elements that strongly repress promoter activity, although it is not clear whether nVDR acts on one of these silencers. Using a promoter analysis program (<http://www.lsi.upc.es/cgi-bin/user/alggen/promo/promo/>

<http://www.lsi.upc.es/cgi-bin/user/alggen/promo/promo/>), we analyzed the human (Genbank accession no. AF208500) and mouse (Genbank accession no. AF115319) UCP2 promoters, which showed that multiple putative nVDR binding sites may exist on UCP2 promoter regions; at least one is located on the silencer regions. Alternatively, nVDR may also compete with other positive transcriptional factors containing similar DNA binding domains on the responsive element binding or a similar protein-protein interaction domain (such as PPAR γ or TR) on heterodimerization with the same transcriptional factor (RXR). This has been evidenced by studies demonstrating that up-regulation or activation of nVDR by $1\alpha,25\text{-(OH)}_2\text{-D}_3$ antagonizes the effects of PPAR γ or TR on adipocyte differentiation. However, further studies are required to address the mechanism whereby $1\alpha,25\text{-(OH)}_2\text{-D}_3$ inhibits UCP2 expression.

Regulation of adipocyte metabolism via $1\alpha,25\text{-(OH)}_2\text{-D}_3$ signaling pathways may play an important role in the development of obesity in vivo. Several lines of evidence demonstrate that the circulating $1\alpha,25\text{-(OH)}_2\text{-D}_3$ level is elevated in obese humans. Since increasing dietary calcium suppresses $1\alpha,25\text{-(OH)}_2\text{-D}_3$ levels, we used this strategy to demonstrate that suppression of $1\alpha,25\text{-(OH)}_2\text{-D}_3$ by increasing dietary calcium decreases adipocyte intracellular Ca^{2+} , stimulates lipolysis, inhibits lipogenesis, and increases adipocyte UCP2 expression and core temperature in aP2-agouti transgenic mice, thereby reducing body weight and fat mass in these animals. Recent data demonstrate comparable effects in humans.

In summary, these data indicate that $1\alpha,25\text{-(OH)}_2\text{-D}_3$ exerts an inhibitory effect on white adipocyte basal, isoproterenol, and fatty acid-stimulated UCP2 expression and that this effect is mediated via a genomic action. Thus, suppression of $1\alpha,25\text{-(OH)}_2\text{-D}_3$ and consequent up-regulation of UCP2 may contribute to our earlier observation of increased thermogenesis in mice fed a high-calcium diet. This effect, coupled with decreased lipogenesis and increased lipolysis secondary to decreased $[\text{Ca}^{2+}]_i$ mediated by nongenomic action, may contribute to an anti-obesity effect of dietary calcium. FJ